Mentoring clinician scientists in patient-oriented substance use disorder research

指导临床科学家进行以患者为导向的物质使用障碍研究

• 批准号: 10720378
• 负责人: JOSEPH T SAKAI
• 金额: $ 19.24万
• 依托单位: UNIVERSITY OF COLORADO DENVER
• 依托单位国家: 美国
• 财政年份: 2023
• 资助国家: 美国
• 起止时间: 2023-06-15 至 2028-05-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10720378
• 关键词: Abstinence; Acceleration; Affect; Aftercare; Animals; Area; Award; Brain; Clinical; Clinical Treatment; Clinical Trials; Crossover Design; Cues; Dedications; Deep Brain Stimulation; Development Plans; Doctor of Philosophy; Evidence based treatment; FDA approved; Fellowship; Funding; Future; Individual; Inpatients; Intervention Studies; Investigation; K-Series Research Career Programs; Leadership; Left; Ligands; Literature; Location; Magnetic Resonance Imaging; Medicine; Mental Depression; Mentors; Mentorship; Meta-Analysis; Methamphetamine; Methamphetamine use disorder; Methods; Midcareer Investigator Award in Patient-Oriented Research; Morbidity - disease rate; Neurobiology; Nucleus Accumbens; Outcome; Outpatients; Pathway interactions; Patient Self-Report; Patient-Focused Outcomes; Patients; Pharmaceutical Preparations; Pharmacotherapy; Physicians; Pilot Projects; Population Scientist Supplement (R25); Positioning Attribute; Postdoctoral Fellow; Prefrontal Cortex; Protocols documentation; Provider; Psychiatry; Randomized; Refractory; Research; Research Personnel; Rest; Rewards; Risk; Role; Sample Size; Scientist; Seizures; Serotonin Receptor 5-HT2A; Site; Substance Use Disorder; Techniques; Testing; Time; Training; Training Programs; Transcranial magnetic stimulation; Treatment Protocols; Treatment outcome; Work; addiction; alcohol use disorder; career; career development; craving; improved; innovation; interest; methamphetamine use; neuroregulation; patient oriented; pilot trial; preventable death; programs; recruit; residential care facility; safety and feasibility; safety testing; secondary outcome; stimulant use; success; treatment research

PROJECT SUMMARY/ABSTRACT: Substance use disorders are prevalent, are associated with serious morbidity and are common causes of preventable death. Although providers have at their disposal a number of evidence-based treatments, such treatments tend to be of near-moderate effect size, leaving some patients as non-responders. Work is needed to enhance existing or develop new treatments with higher effects sizes. This mid-career investigator award in patient-oriented research would enable Joseph Sakai, MD release from clinical and administrative duties to allow continued career development activities, to expand his lab’s work on neuromodulation and addiction and to provide high-quality mentorship to early career investigators. Dr. Sakai is involved in several medication trials for the treatment of alcohol use disorder and is contact PI for a UG3 award to test deep brain stimulation for treatment refractory methamphetamine use disorder utilizing a crossover design. This mid-career award, if funded, would allow Dr. Sakai’s lab to test the safety and feasibility of an accelerated transcranial magnetic stimulation treatment protocol for methamphetamine use disorder. In addition, this trial would allow effect size estimation to power a future trial. Each project allows key opportunities for trainee participation and mentorship as described in the application. Dr. Sakai is director of the CU-Pathways resident research track, which seeks to develop research-oriented physician scientists in the Department of Psychiatry. Because of that program’s successes, CU was awarded an R25 to support that track and match 2 residents per year through the NRMP (Sakai MPI). Dr. Sakai has also been very active with the DPRG T32 post-doctoral research fellowship training program which was renewed in 2022 (Sakai is associate director, and is primary mentor for 2 post-docs in that program). Thus, Dr. Sakai has formalized roles within major departmental mentorship programs with a specific focus on physician scientists; all programs emphasize and value recruitment of individuals from backgrounds under-represented in medicine.

项目总结/摘要： 物质使用障碍很普遍，与严重的发病率有关，是导致精神疾病的常见原因。 可预防的死亡虽然提供者有一些基于证据的治疗方法， 治疗往往是接近中等的效果大小，留下一些患者作为无反应者。工作是需要在 以增强现有的或开发具有更高效应量的新治疗方法。这个职业生涯中期的调查奖， 以病人为导向的研究将使约瑟夫酒井，医学博士从临床和行政职责释放， 继续职业发展活动，扩大他的实验室在神经调节和成瘾方面的工作， 为早期职业调查人员提供高质量的指导。酒井博士参与了几项药物试验， 酒精使用障碍的治疗，并联系PI获得UG 3奖，以测试脑深部电刺激， 利用交叉设计治疗难治性甲基苯丙胺使用障碍。这个职业生涯中期的奖项，如果 这将使酒井博士的实验室能够测试加速经颅磁共振成像的安全性和可行性。 甲基苯丙胺使用障碍刺激治疗方案。此外，该试验将允许效应量 为未来的审判提供动力。每个项目都为学员参与和指导提供了重要机会 如本申请中所述。酒井博士是CU-Pathways居民研究跟踪的主任，该研究旨在 在精神病学系培养研究型的医生科学家。因为这个项目 成功，CU被授予R25，以支持通过NRMP每年跟踪和匹配2名居民 （Sakai MPI）。酒井博士还积极参加了DPRG T32博士后研究奖学金培训 2022年更新的项目（酒井是副主任，是2名博士后的主要导师， 程序）。因此，酒井博士在主要的部门指导计划中正式确定了角色， 专注于医生科学家;所有计划都强调并重视从背景中招募个人 在医学界的代表性不足。